Context Therapeutics Inc. (CNTX) Business Analysis — Annual Report Summary, Outlook & Risks

Overview Financials Chart Business Summary Filings Ownership Valuation

Context Therapeutics Inc. (CNTX)

Business Summary

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. The company's core business model revolves around the discovery, development, and potential commercialization of these novel therapeutic candidates. Revenue generation is currently absent, with the company incurring recurring losses and negative cash flows from operations, primarily attributable to research and development activities ¹. The company's strategy includes rapidly advancing its clinical programs, expanding its pipeline through in-licensing or acquisitions, and evaluating strategic opportunities to accelerate development timelines and enhance commercial potential, including potential out-licensing of assets ².

The company's pipeline consists of three main product candidates: CTIM-76, CT-95, and CT-202. CTIM-76 is a Claudin 6 (CLDN6) x CD3 TCE designed to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6, a protein highly prevalent in multiple solid tumors and minimally expressed in healthy adult tissues ³. The company believes CTIM-76 offers differentiation due to its high selectivity for CLDN6 over other Claudin proteins and its potential to target tumors with varying levels of CLDN6 expression, potentially broadening the target patient population ⁴. The estimated patient population for CLDN6-positive relapse/refractory (R/R) disease in the United States is greater than 50,000 patients per year ⁵. Initial indications of interest include ovarian, endometrial, and testicular cancers, with estimated R/R patient populations of 9,600, 7,000, and 400, respectively, for CLDN6 Med/High expression ⁶.

CT-95 is a Mesothelin (MSLN) x CD3 TCE intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN, a membrane protein overexpressed in approximately 30% of cancers ⁷. CT-95 is a fully humanized bispecific T cell engager with moderate affinity but high avidity for membrane-bound MSLN, designed to minimize the impact of shed MSLN fragments that can act as a decoy ⁸. The company believes CT-95 is differentiated by its binding to the membrane-proximal side of MSLN, which may increase potency, and its avidity enhancement to minimize adverse events like cytokine release syndrome and hypoxia ⁹. The estimated patient population for MSLN-positive R/R disease in the United States is greater than 100,000 patients per year ¹⁰. Initial indications of interest include non-small cell lung, pancreatic, and colon cancers, with estimated R/R patient populations of 60,859, 41,400, and 21,734, respectively, for MSLN Med/High expression ¹¹.

CT-202 is a Nectin-4 x CD3 TCE that targets Nectin-4, a cell surface protein highly overexpressed in various solid tumors ¹². CT-202 is a pH-dependent TCE designed to be preferentially active within the acidic tumor microenvironment, aiming to reduce dermatologic side effects associated with Nectin-4 expression in the skin ¹³. The company believes CT-202 is differentiated by its pH-dependent binding and avidity enhancement to mitigate cytokine release syndrome risk ¹⁴. The estimated patient population for Nectin-4-positive R/R disease in the United States is greater than 125,000 patients per year ¹⁵. Initial indications of interest include colon, bladder (urothelial), and breast (TNBC) cancers, with estimated R/R patient populations of 46,119, 16,600, and 12,090, respectively, for Nectin-4 Med/High expression ¹⁶.

For the fiscal year ended December 31, 2025, Context Therapeutics reported a net loss of $36,123,615 ¹⁷. Operating expenses totaled $39,702,631 ¹⁸, comprising research and development expenses of $31,856,252 ¹⁹ and general and administrative expenses of $7,846,379 ²⁰. Interest income was $3,378,545 ²¹, and other income was $200,471 ²². The basic and diluted net loss per common share was $(0.38) ²³. As of December 31, 2025, the company had cash and cash equivalents of $65,995,228 ²⁴ and an accumulated deficit of $130,903,309 ²⁵. Total assets were $68,493,768 ²⁶, and total liabilities were $8,020,041 ²⁷.

Comparing the fiscal year 2025 to 2024, research and development expenses increased by approximately $9.2 million ²⁸, or 40% ²⁹, from $22,701,335 to $31,856,252 ³⁰. This increase was primarily driven by a $3.1 million increase in CTIM-76 clinical costs due to trial progression ³¹, a $4.4 million increase in CT-202 expenses, mainly from $8.7 million in contract manufacturing costs, $4.7 million in preclinical expenses, and a $2.0 million development milestone payment ³², and a $3.3 million increase in personnel-related costs due to higher headcount and termination benefits ³³. General and administrative expenses increased by $0.6 million ³⁴, or 9% ³⁵, from $7,222,565 to $7,846,379 ³⁶, primarily due to a $0.7 million increase in salaries and personnel-related costs ³⁷. Interest income increased by approximately $0.2 million ³⁸, or 6% ³⁹, due to higher cash and cash equivalent balances ⁴⁰. Other income shifted from an expense of $1,428 in 2024 to an income of $200,471 in 2025, primarily due to foreign currency gains ⁴¹.

During the reported period, Context Therapeutics dosed the first patient in its CTIM-76 Phase 1 trial in January 2025 ⁴² and the first patient in its CT-95 Phase 1 trial in April 2025 ⁴³. The company acquired CT-95 from Link (assignment for the benefit of creditors), LLC for a one-time payment of $3.75 million on July 9, 2024 ⁴⁴. On September 23, 2024, Context Therapeutics entered into a license agreement with BioAtla, Inc. to obtain exclusive worldwide rights to develop, manufacture, and commercialize two licensed antibodies, including BA3362 (renamed CT-202), making an upfront payment of $11.0 million ⁴⁵. In October 2025, the company achieved a $2.0 million development milestone under the BioAtla License Agreement ⁴⁶. The company also amended its Integral License Agreement on February 29, 2024, reducing aggregate development and regulatory milestone payments from $55 million to $15 million, sales milestone payments from $130 million to $12.5 million, and the tiered royalty rate to a flat 6% on net sales beginning no sooner than February 1, 2034 ⁴⁷.

Business Outlook & Financial Sufficiency

Context Therapeutics expects its cash and cash equivalents of $65.995 million as of December 31, 2025, to fund its projected operations into mid-2027 ⁴⁸. This funding is anticipated to cover the estimated duration of the Phase 1a dose escalation portions of its CTIM-76 and CT-95 trials, as well as the estimated expenses to initiate patient enrollment in a first-in-human trial for CT-202 ⁴⁹. The company will need substantial additional capital to support its continuing operations and pursue its growth strategy, planning to finance operations through a combination of equity offerings, debt financings, collaborations, strategic transactions, and/or marketing, distribution, or licensing arrangements ⁵⁰.

The company is focused on rapidly advancing its CTIM-76 and CT-95 clinical programs through Phase 1 proof of concept. For CTIM-76, the company expects to share Phase 1a interim data in June 2026 ⁵¹. For CT-95, Phase 1a interim data is expected to be shared in September 2026 ⁵². These milestones are critical for demonstrating the safety and tolerability of the product candidates and evaluating preliminary anti-tumor activity to select doses and schedules for future trials ⁵³.

A key growth area is the rapid advancement of CT-202 into clinical development. The company submitted its application to the Australian Bellberry Human Research Ethics Committee (HREC) in March 2026 to support the initiation of a first-in-human trial for CT-202 ⁵⁴. The first patient in the CT-202 Phase 1 trial is expected to be dosed in the third quarter of 2026 ⁵⁵. This program targets Nectin-4, a clinically validated target, with CT-202 designed as a pH-dependent TCE to preferentially activate within the tumor microenvironment, potentially reducing dermatologic side effects and capturing a broader patient population ⁵⁶.

Operationally, the company expects its research and development expenses to increase significantly over the next several years as it increases personnel costs, including share-based compensation, conducts clinical trials (including later-stage trials), and prepares regulatory filings for current and future product candidates ⁵⁷. General and administrative expenses are also expected to increase to support continued research and development, potential commercialization efforts, and increased costs of operating as a public company, including hiring additional personnel and fees for outside consultants, legal support, and accountants ⁵⁸. If any product candidates obtain U.S. regulatory approval, the company expects to incur significantly increased expenses associated with building a sales and marketing team ⁵⁹.

The company does not own or operate manufacturing facilities and relies on third parties for the manufacture of its product candidates for preclinical and clinical testing, and for commercial manufacture if approved ⁶⁰. It also relies on third parties for packaging, labeling, storage, and distribution ⁶¹. The company continues to develop its supply chain for CTIM-76, CT-95, and CT-202, intending to establish additional framework agreements with third-party contract manufacturers ⁶². The Lonza CTIM-76 License Agreement and Lonza CT-202 License Agreement involve potential annual payments of up to less than $500,000 per asset and royalties on net sales from 0% up to a low single-digit percentage ⁶³.

Planned capital allocation includes continued significant investment in research and development. The company's future funding requirements will depend on the scope, timing, progress, and results of discovery, preclinical development, laboratory testing, and clinical trials, as well as manufacturing costs, intellectual property costs, and expenses for attracting and retaining skilled personnel ⁶⁴. The company may also seek to acquire or in-license additional product candidates or technologies ⁶⁵.

Management explicitly flagged several structural headwinds and execution risks. The company has never been profitable and may never achieve or maintain profitability, requiring substantial additional development time and resources before any product revenue may be realized ⁶⁶. There is a need to raise additional funding, which may not be available on acceptable terms or at all, potentially forcing delays, reductions, or termination of product development efforts ⁶⁷. The process of identifying product candidates and conducting trials is time-consuming, expensive, and uncertain ⁶⁸. The company's reliance on a central team of limited employees and consultants presents operational challenges ⁶⁹, and its future success depends on retaining key executives and attracting qualified personnel ⁷⁰.

Geographic, regulatory, and macro factors identified as constraints include fluctuating foreign exchange rates that could increase operating expenses ⁷¹, and inflation, geopolitical developments, and global supply chain disruptions that could adversely affect business and results of operations ⁷². Changes in U.S. trade policy, including tariffs, may also have a material adverse impact ⁷³. The FDA regulatory approval process is lengthy and time-consuming, and the novel nature of the product candidates may create further challenges ⁷⁴. CTIM-76, CT-95, and CT-202 are expected to be regulated as biologics, potentially subject to competition from biosimilar applicants after a 12-year exclusivity period, which could be shortened ⁷⁵. Obtaining regulatory approval in one jurisdiction does not guarantee approval in others, and foreign regulatory processes can involve additional requirements and longer review periods ⁷⁶. Even if approved, products may not gain market acceptance among the medical community ⁷⁷, and coverage and reimbursement may be limited or unavailable, making profitable sales difficult ⁷⁸. The advancement of healthcare reform, such as the Inflation Reduction Act of 2022, could negatively impact the ability to sell products profitably due to price negotiation and cost containment programs ⁷⁹. Changes to U.S. federal regulatory agencies, including potential budget reductions or restructuring, could cause disruptions and delays in government approval processes ⁸⁰.

Management Sentiments & Priorities

Management's overall tone emphasizes the company's focus as a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, with a clear goal to build an innovative portfolio of TCE bispecific therapeutics. They highlight the ongoing clinical development of CTIM-76 and CT-95, with the first patient dosed in the CTIM-76 Phase 1 trial in January 2025 ⁹² and the first patient dosed in the CT-95 Phase 1 trial in April 2025 ⁹³. A key strategic priority is the rapid advancement of CT-202 into clinical development, with the application submitted to the HREC in March 2026 and the expectation to dose the first patient in the CT-202 Phase 1 trial in the third quarter of 2026 ⁹⁴. Management also communicated specific forward-looking guidance regarding interim data, expecting to share Phase 1a interim data for the CTIM-76 trial in June 2026 ⁹⁵ and for the CT-95 trial in September 2026 ⁹⁶. A critical strategic priority is the continued evaluation of opportunities to expand the pipeline through development, in-licensing, or acquisition of assets with therapeutic potential against identified selective cancer targets, alongside evaluating strategic opportunities to accelerate development timelines and enhance commercial potential globally, including potential out-licensing ⁹⁷. Management acknowledges the need for additional funding to meet operational needs and capital requirements for clinical trials and other R&D expenditures, stating that current cash and cash equivalents of $65.995 million as of December 31, 2025, are expected to fund operations into mid-2027 ⁹⁸.

Risk Factors

Context Therapeutics faces material risks including its history of unprofitability and the potential inability to achieve or maintain profitability, necessitating substantial additional funding that may not be available on acceptable terms, potentially forcing delays or termination of product development efforts ⁸¹. The business is highly dependent on the successful development, regulatory approval, and commercialization of its early-stage product candidates (CTIM-76, CT-95, CT-202), with preclinical and early clinical trial results not being indicative of later-stage success, and any product candidate may cause serious adverse events or undesirable side effects ⁸². The company may find it difficult to enroll patients in clinical trials, leading to delays ⁸³. Operational risks include reliance on a limited central team of fifteen full-time employees ⁸⁴ and consultants, and the challenge of retaining key executives and attracting qualified personnel ⁸⁵. The company relies heavily on third parties for research, development, commercialization, and manufacturing, and any failure by these parties could harm business prospects ⁸⁶. Intellectual property risks are significant, with patents involving complex legal questions, potential claims of infringement from third parties (e.g., patents expiring in January 2034 and March 2042 potentially covering CTIM-76 ⁸⁷), and the difficulty of protecting intellectual property rights globally ⁸⁸. Regulatory risks include the lengthy FDA approval process, the classification of product candidates as biologics potentially subject to biosimilar competition, and the possibility of the FDA disagreeing with regulatory plans or requiring additional studies ⁸⁹. Macroeconomic and geopolitical risks include fluctuating foreign exchange rates, inflation, global supply chain disruptions, and changes in U.S. trade policy, including tariffs, which could increase operating expenses and impact financial condition ⁹⁰. Cybersecurity threats, while not yet materially affecting the company, remain a risk to information systems and data integrity ⁹¹.

View Source Annual Report on SEC.gov ↗

References

[1] Item 7, MD&A — Overview
[2] Item 1, Business — Our Strategy
[3] Item 1, Business — Overview
[4] Item 1, Business — CLDN6xCD3 TCE program: CTIM-76
[5] Item 1, Business — Market Opportunity (CLDN6xCD3 TCE program: CTIM-76)
[6] Item 1, Business — Market Opportunity (CLDN6xCD3 TCE program: CTIM-76)
[7] Item 1, Business — Mesothelin x CD3 TCE program: CT-95
[8] Item 1, Business — Mesothelin x CD3 TCE program: CT-95
[9] Item 1, Business — Mesothelin x CD3 TCE program: CT-95
[10] Item 1, Business — Market Opportunity (Mesothelin x CD3 TCE program: CT-95)
[11] Item 1, Business — Market Opportunity (Mesothelin x CD3 TCE program: CT-95)
[12] Item 1, Business — Nectin-4 x CD3 TCE program: CT-202
[13] Item 1, Business — Nectin-4 x CD3 TCE program: CT-202
[14] Item 1, Business — Nectin-4 x CD3 TCE program: CT-202
[15] Item 1, Business — Market Opportunity (Nectin-4 x CD3 TCE program: CT-202)
[16] Item 1, Business — Market Opportunity (Nectin-4 x CD3 TCE program: CT-202)
[17] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
[18] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
[19] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
[20] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
[21] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
[22] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
[23] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
[24] Item 7, MD&A — Financial Overview
[25] Item 7, MD&A — Financial Overview
[26] Item 8, Consolidated Balance Sheets
[27] Item 8, Consolidated Balance Sheets
[28] Item 7, MD&A — Research and Development Expenses
[29] Item 7, MD&A — Research and Development Expenses
[30] Item 7, MD&A — Research and Development Expenses
[31] Item 7, MD&A — Research and Development Expenses
[32] Item 7, MD&A — Research and Development Expenses
[33] Item 7, MD&A — Research and Development Expenses
[34] Item 7, MD&A — General and Administrative Expenses
[35] Item 7, MD&A — General and Administrative Expenses
[36] Item 7, MD&A — General and Administrative Expenses
[37] Item 7, MD&A — General and Administrative Expenses
[38] Item 7, MD&A — Interest Income
[39] Item 7, MD&A — Interest Income
[40] Item 7, MD&A — Interest Income
[41] Item 7, MD&A — Other Income (Expense)
[42] Item 1, Business — CLDN6xCD3 TCE program: CTIM-76
[43] Item 1, Business — Mesothelin x CD3 TCE program: CT-95
[44] Item 1, Business — Asset Purchase Agreement with Link
[45] Item 1, Business — Collaboration and Licensing Agreement with BioAtla
[46] Item 7, MD&A — CT-202: BioAtla License Agreement
[47] Item 1, Business — Collaboration and Licensing Agreement with Integral Molecular
[48] Item 7, MD&A — Financial Overview
[49] Item 7, MD&A — Financial Overview
[50] Item 7, MD&A — Financial Overview
[51] Item 1, Business — Our Strategy
[52] Item 1, Business — Our Strategy
[53] Item 1, Business — Clinical Development Plan (CLDN6xCD3 TCE program: CTIM-76)
[54] Item 1, Business — Our Strategy
[55] Item 1, Business — Our Strategy
[56] Item 1, Business — Nectin-4 x CD3 TCE program: CT-202
[57] Item 7, MD&A — Research and Development Expenses
[58] Item 7, MD&A — General and Administrative Expenses
[59] Item 7, MD&A — General and Administrative Expenses
[60] Item 1, Business — Manufacturing
[61] Item 1, Business — Manufacturing
[62] Item 1, Business — Manufacturing
[63] Item 1, Business — Manufacturing
[64] Item 7, MD&A — Funding Requirements
[65] Item 7, MD&A — Funding Requirements
[66] Item 1A, Risk Factors — We have never been profitable and may never achieve or maintain profitability.
[67] Item 1A, Risk Factors — We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.
[68] Item 1A, Risk Factors — If we are unable to raise substantial additional capital on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts.
[69] Item 1A, Risk Factors — Our reliance on a central team consisting of a limited number of employees and consultants who provide various administrative, research and development, and other services across our organization presents operational challenges that may adversely affect our business.
[70] Item 1A, Risk Factors — Our future success depends on our ability to retain our Chief Executive Officer, Chief Medical Officer, Chief Financial Officer, Chief Legal Officer, and other key executives and to attract, retain and motivate qualified personnel.
[71] Item 1A, Risk Factors — Fluctuating foreign exchange rates could increase our operating expenses and adversely affect our results of operations.
[72] Item 1A, Risk Factors — Inflation, geopolitical developments, global supply chain disruptions and public health concerns could adversely affect our business and results of operations.
[73] Item 1A, Risk Factors — Changes in U.S. trade policy, including the imposition of tariffs and the resulting consequences, may have a material adverse impact on our business, financial condition, and results of operations.
[74] Item 1A, Risk Factors — The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our current and any future product candidates.
[75] Item 1A, Risk Factors — We expect that CTIM-76, CT-95 and CT-202 will be regulated as biological products, or biologics, and therefore they may be subject to competition from biosimilar applicants.
[76] Item 1A, Risk Factors — Obtaining and maintaining regulatory approval of a product candidate in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of such product candidate in other jurisdictions.
[77] Item 1A, Risk Factors — Even if we obtain regulatory approval of a product candidate, the product may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.
[78] Item 1A, Risk Factors — Coverage and reimbursement may be limited or unavailable in certain market segments for a product candidate, which could make it difficult for us to sell such product candidate, if approved, profitably.
[79] Item 1A, Risk Factors — The advancement of healthcare reform may negatively impact our ability to sell our current and any future product candidates, if approved, profitably.
[80] Item 1A, Risk Factors — Changes to United States federal regulatory agencies may cause disruptions and delays in government approval processes and regulations relating to our product candidates.
[81] Item 1A, Risk Factors — We have never been profitable and may never achieve or maintain profitability.
[82] Item 1A, Risk Factors — Our business is dependent on the successful development, regulatory approval and commercialization of our therapeutic product candidates, CTIM-76, CT-95 and CT-202, which are in the early stages of development.
[83] Item 1A, Risk Factors — We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties or delays enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
[84] Item 1A, Risk Factors — Our reliance on a central team consisting of a limited number of employees and consultants who provide various administrative, research and development, and other services across our organization presents operational challenges that may adversely affect our business.
[85] Item 1A, Risk Factors — Our future success depends on our ability to retain our Chief Executive Officer, Chief Medical Officer, Chief Financial Officer, Chief Legal Officer, and other key executives and to attract, retain and motivate qualified personnel.
[86] Item 1A, Risk Factors — We expect to, and do, depend on collaborations with third parties for certain research, development and commercialization activities, and if any such collaborations are not successful, it may harm our business and prospects.
[87] Item 1A, Risk Factors — Third parties may assert claims against us alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of our current and any future product candidates, prohibit our use of proprietary technology or sale of potential products or put our patents and other proprietary rights at risk.
[88] Item 1A, Risk Factors — Our ability to compete effectively in our markets may decline if we do not adequately protect our proprietary rights, and our proprietary rights do not necessarily address all potential threats to our competitive advantages.
[89] Item 1A, Risk Factors — The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our current and any future product candidates.
[90] Item 1A, Risk Factors — Fluctuating foreign exchange rates could increase our operating expenses and adversely affect our results of operations.
[91] Item 1C, Cybersecurity — Risks from Cybersecurity Threats
[92] Item 7, MD&A — Overview
[93] Item 7, MD&A — Overview
[94] Item 7, MD&A — Overview
[95] Item 7, MD&A — Overview
[96] Item 7, MD&A — Overview
[97] Item 1, Business — Our Strategy
[98] Item 7, MD&A — Financial Overview

Analysis on 5/20/2026

Recent Material Events

Jul 31, 2026Material Event

Context Therapeutics Inc. received a notice from Nasdaq on July 29, 2026, stating its common stock failed to maintain the $1.00 minimum closing bid price for 30 consecutive business days under Listing Rule 5550(a)(2). The company has an initial 180-day compliance period ending January 25, 2027, during which it must restore a closing bid price of at least $1.00 for ten consecutive business days to regain compliance. Failure to meet this requirement may trigger eligibility for a second 180-day period contingent on meeting market value standards and notifying Nasdaq. If the company cannot demonstrate an ability to comply within these periods, its shares will be subject to delisting, though it retains the right to appeal such determination to a Nasdaq Hearings Panel. Context Therapeutics Inc. operates in the biotechnology industry, focusing on developing therapies for rare diseases.

Jun 26, 2026Material Event

On June 24, 2026, Context Therapeutics Inc. stockholders approved an amendment to the company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000. The company also elected seven directors and ratified CohnReznick LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. Context Therapeutics Inc. is a biotechnology company that develops therapeutics for the treatment of cancer.

Jun 15, 2026Material Event

Context Therapeutics Inc. announced positive interim efficacy and safety results from its ongoing Phase 1 clinical trial for CTIM-76, an investigational Claudin 6 x CD3 T cell engaging bispecific antibody. The company also updated its corporate presentation and hosted a conference call to discuss the clinical trial data. Context Therapeutics Inc. is a biotechnology company focused on developing investigational therapeutics for cancer.